BNTC
Benitec Biopharma Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.36
+3.08%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- -13.9%
- EBIT
- -29.4%
- EPS
- +38.0%
- Free cash flow
- +28.6%
- Operating cash flow
- +29.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +44.1%
- EPS
- -31.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- -22.6%
- EBIT
- -22.6%
- Net income
- -20.1%
- EPS
- +6.7%
- Free cash flow
- +29.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026